Gilead Sciences

NASDAQ: GILD
$70.27
+$0.20 (+0.3%)
Closing price November 26, 2021
These four high-conviction health care stock ideas from the analysts at Jefferies all make sense for investors looking to gain exposure to a sector that should continue to do well the rest of 2020...
Immunomedics shares more than doubled on Monday after the firm announced that it would be acquired by Gilead Sciences in one of the biggest deals to go down in the health care sector this year.
Monday's top analyst upgrades and downgrades included Adobe, BP, FedEx, GameStop, Gilead Sciences, Kroger, MGM Resorts, Micron Technology, Nvidia and Tradeweb Markets.
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five...
Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc. (NASDAQ: GILD). This deal is for the discovery and...
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The FDA has come down on an investigational treatment for moderately to severely active from Gilead Sciences and Galapagos.
Wednesday's top analyst upgrades and downgrades included Agilent Technologies, Cree, Deere, Gilead Sciences, Home Depot, Kohl's, Nordstrom, Walmart and Walt Disney.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering how...
The run-up in equity prices related to the COVID-19 outbreak combined with the federal government's efforts to soften the financial damage due to the pandemic have driven equity prices sharply...